A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk and Vivani have announced a partnership to develop a long-acting semaglutide implant designed to assist with long-term weight loss.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Novo Nordisk has entered into a formal agreement with the biotech firm Vivani. The companies are collaborating on the development of a tiny, implantable device intended to deliver semaglutide to patients over extended periods.
Coverage from outlets including CNBC, Yahoo Finance, and Pluang emphasizes the potential for the implant to improve treatment adherence for GLP-1 users. Reports note that the device is currently being evaluated for a duration that could potentially last up to a year.
Future updates are expected to track the progress of the partnership and the clinical development of the implant technology. Current coverage does not yet specify a timeline for potential regulatory submissions or human trials.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What is the primary function of the new implant?
The implant is designed to deliver semaglutide to patients to help maintain weight loss and improve adherence to treatment.
Which companies are involved in this development?
Novo Nordisk and Vivani have signed a partnership agreement to develop the technology.
How long is the implant expected to last?
Current reports indicate that the device is being evaluated to potentially last up to a year.
Coverage (5)
- Vivani develops semaglutide implant to improve long-term weight loss adherence for GLP-1 users Pluang · 2h ago
- Ozempic & Wegovy Maker To Evaluate Long-Acting GLP-1 Implant That Could Last Up To A Year Health and Me · 2h ago
- Biotech CEO on new Novo Nordisk partnership: “This could be big” medwatch.com · 2h ago
- Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant Yahoo Finance · 2h ago
- A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss CNBC · 2h ago broke it first
People, places & organizations
Topics
Related trends
Which ‘AI scientist’ suits your lab? A guide for the perplexed
5 news sources are covering this Technology story right now — Newsylist is tracking how fast it spreads.
The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy
New clinical trial data involving stem cell-derived dopaminergic cells has spurred AI-driven interest in Parkinson's disease treatment.
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
American biopharma firms are adopting more secretive operational strategies as competition with China’s expanding bioeconomy intensifies.
Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs
6 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
Nestlé to Tweak Some Food Recipes to Appeal to Duller GLP-1 Palates
6 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
11% of Americans Are Currently Taking a GLP-1 Weight Loss Drug Like Wegovy
8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.